Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
Want to see CNTB full AI Analyst Report?
Top Page
Connect Biopharma Holdings
(NASDAQ:CNTB)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.50
▼(-11.03% Downside)
Action:ReiteratedDate:04/24/26
The score is held down primarily by weak financial performance (zero revenue in 2025, large losses, and significant ongoing cash burn), with additional pressure from soft technical momentum. Offsetting these risks, corporate updates were constructive (positive trial safety/interim review and added financing extending runway), but valuation metrics remain unattractive due to continued losses and no dividend data.
Positive Factors
DMC Interim Review / Safety
An independent Data Monitoring Committee found no safety concerns and allowed enrollment to continue, materially de-risking rademikibart's development path. Durable impact: maintaining trial timelines preserves probability of reaching pivotal data and engaging regulators for Phase 3 planning, sustaining long-term asset value if efficacy follows safety.
Negative Factors
Persistent Cash Burn
The company generates materially negative operating and free cash flow, indicating structural cash consumption to fund R&D and trials. Over the medium term this necessitates recurring external financing or major cost cuts, which can dilute shareholders or slow development if capital markets tighten, creating sustained execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
DMC Interim Review / Safety
An independent Data Monitoring Committee found no safety concerns and allowed enrollment to continue, materially de-risking rademikibart's development path. Durable impact: maintaining trial timelines preserves probability of reaching pivotal data and engaging regulators for Phase 3 planning, sustaining long-term asset value if efficacy follows safety.
Read all positive factors
Connect Biopharma Holdings (CNTB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$139.61M
Dividend YieldN/A
Average Volume (3M)97.97K
Price to Earnings (P/E)―
Beta (1Y)-0.29
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees62
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.27
Shares Outstanding56,521,282
10 Day Avg. Volume111,495
30 Day Avg. Volume97,966
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.74
Price to Sales (P/S)2452.52
P/FCF Ratio-3.04
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.12K
Enterprise Value/Gross Profit2.12K
Enterprise Value/Ebitda-3.57
Forecast
1Y Price Target
$8.38Price Target Upside198.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.18
Revenue Forecast (FY)$51.69M
Connect Biopharma Holdings Business Overview & Revenue Model
Company Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate i...
How the Company Makes Money
Connect Biopharma is a clinical-stage biotech and, based on publicly available descriptions of its stage of development, it has historically not had recurring product sales as a primary revenue source (null for material commercial revenue from mar...
Connect Biopharma Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 64.00K | 26.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 64.00K | 26.03M | 0.00 | 0.00 | 0.00 |
| EBITDA | -57.37M | -21.79M | -68.34M | -116.74M | -201.36M |
| Net Income | -55.48M | -15.63M | -62.11M | -118.09M | -202.27M |
Balance Sheet | |||||
| Total Assets | 56.08M | 101.28M | 127.38M | 174.01M | 291.05M |
| Cash, Cash Equivalents and Short-Term Investments | 44.34M | 93.71M | 118.30M | 152.42M | 267.72M |
| Total Debt | 690.00K | 178.00K | 465.00K | 431.00K | 125.00K |
| Total Liabilities | 14.10M | 9.12M | 25.88M | 16.52M | 18.80M |
| Stockholders Equity | 41.98M | 92.17M | 101.50M | 157.49M | 272.26M |
Cash Flow | |||||
| Free Cash Flow | -51.64M | -24.36M | -48.22M | -103.55M | -93.03M |
| Operating Cash Flow | -51.21M | -23.61M | -47.93M | -99.27M | -85.57M |
| Investing Cash Flow | 9.82M | -3.45M | 75.16M | -83.44M | -5.34M |
| Financing Cash Flow | 1.09M | 227.00K | -246.00K | -91.28K | 206.66M |
Connect Biopharma Holdings Technical Analysis
Positive
2.81
Price Trends
2.77
Positive
2.63
Positive
2.21
Positive
Market Momentum
0.03
Positive
48.71
Neutral
58.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTB, the sentiment is Positive. The current price of 2.81 is below the 20-day moving average (MA) of 2.95, above the 50-day MA of 2.77, and above the 200-day MA of 2.21, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 48.71 is Neutral, neither overbought nor oversold. The STOCH value of 58.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNTB.
Connect Biopharma Holdings Risk Analysis
Connect Biopharma Holdings disclosed 121 risk factors in its most recent earnings report. Connect Biopharma Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
The proposed revision of the EU legislation on pharmaceuticals could lead to uncertainties over the regulatory framework that will be applicable to medicinal products in the EU, including orphan medicinal products. Q4, 2023
2.
We are subject to risks arising from potential health epidemics. Q4, 2023
Connect Biopharma Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $139.61M | -2.83 | -49.43% | ― | ― | ― | |
44 Neutral | $2.46M | -0.20 | ― | ― | 99.48% | -474.47% | |
44 Neutral | $5.35M | -0.28 | -203.36% | ― | ― | 93.60% | |
43 Neutral | $10.84M | -0.15 | -356.99% | ― | ― | -108.12% | |
42 Neutral | $4.17M | -0.22 | -0.40% | ― | ― | 96.30% |
* Healthcare Sector Average
CNTB
Connect Biopharma Holdings
2.47
1.68
212.66%
SCNI
Scinai Immunotherapeutics
0.71
-2.19
-75.52%
GTBP
GT Biopharma
0.34
-1.95
-85.02%
REVB
Revelation Biosciences
1.12
-33.69
-96.78%
DRMA
Dermata Therapeutics
1.33
-7.22
-84.44%
CERO
CERo Therapeutics Holdings
0.03
-15.77
-99.79%
Connect Biopharma Holdings Corporate Events
Business Operations and StrategyProduct-Related Announcements
Connect Biopharma Advances Rademikibart After Positive Interim Review
Positive
Apr 23, 2026
On April 23, 2026, Connect Biopharma reported that an independent Data Monitoring Committee completed a pre-specified interim efficacy analysis of its Phase 2 Seabreeze STAT trials in acute asthma and COPD, with no recommendation to change sample ...
Business Operations and StrategyPrivate Placements and Financing
Connect Biopharma Highlights Positive Rademikibart Respiratory Trial Results
Positive
Mar 30, 2026
On March 29, 2026, Connect Biopharma entered into a securities purchase agreement for a $20.2 million private placement of 6,130,000 ordinary shares at $3.25 per share, with closing expected on March 31, 2026, to strengthen its balance sheet under...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.